Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BioChaperone Pramlintide Insulin in Type 1 Diabetes
NCT03512236Phase 1Completed
- Sponsor
- Adocia
- Start
- Apr 2018
- Primary completion
- Feb 2019
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BC LisPram in type 1 diabetes mellitus (T1D) (3 arms), sponsored by Adocia. Primary endpoints: Maximum Observed Plasma Concentration for Pramlintide and Area Under the Plasma Concentration-Time Curve for Pramlintide. Started Apr 2018; status: completed.
02
Drugs
BC LisPram
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03512236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03512236.